PTPIOTCPharmaceutical PreparationsFiscal year ends December 31
Petros Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.00+0.00 (+5.56%)
Close on Oct 19, 2026
- Market cap
- $135.07K
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Who owns Petros Pharmaceuticals's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B | 657,614 | 6.20% | 13G (passive) amendment | Dec 31, 2024 |
| Iroquois Capital Management, LLC | 5,939,954 | 9.99% | 13G (passive) amendment | Mar 31, 2025 |
| Richard Abbe | 4,434,773 | 9.99% | 13G (passive) amendment | Dec 21, 2025 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Robert Weinstein | Chief Accounting Officer | 636,004 | 1.50% | Jun 25, 2026 |
| Fady Boctor | See Remarks | 894,986 | 2.11% | Jun 5, 2026 |
| Mitchell Arnold | See Remarks | 150,390 | 0.35% | Feb 21, 2025 |
| Wayne Remell Walker | Director | 881,333 | 2.08% | Jun 8, 2026 |
| Joshua Silverman | Director | 8,790,450 | 20.75% | Jun 5, 2026 |
| Bruce Bernstein | Director | 3,762,334 | 8.88% | Jun 5, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Wayne Remell Walker Director | Jun 5, 2026 | Award | +375,000 | – | – | 881,333 |
| Bruce Bernstein Director | Jun 5, 2026 | Award | +1,875,000 | – | – | 3,762,334 |
| Fady Boctor See Remarks | Jun 5, 2026 | Award | +375,000 | – | – | 894,986 |
| Joshua Silverman Director | Jun 5, 2026 | Award | +4,375,000 | – | – | 8,790,450 |
| Fady Boctor See Remarks | Jan 2, 2026 | Award | +500,000 | – | – | 519,986 |
| Joshua Silverman Director | Jan 2, 2026 | Award | +4,375,000 | – | – | 4,415,450 |
| Wayne Remell Walker Director | Jan 2, 2026 | Award | +500,000 | – | – | 506,333 |
| Bruce Bernstein Director | Jan 2, 2026 | Award | +1,875,000 | – | – | 1,887,334 |
| Mitchell Arnold See Remarks | Feb 19, 2025 | Award | +150,000 | – | – | 150,000 |
| Fady Boctor See Remarks | Feb 19, 2025 | Award | +450,000 | – | – | 499,645 |
| Wayne Remell Walker Director | Feb 19, 2025 | Award | +150,000 | – | – | 158,314 |
| Joshua Silverman Director | Feb 19, 2025 | Award | +1,000,000 | – | – | 1,011,237 |
| Bruce Bernstein Director | Feb 19, 2025 | Award | +300,000 | – | – | 308,346 |
| Fady Boctor See Remarks | Dec 21, 2023 | Award | +49,645 | – | – | 49,645 |
| Bruce Bernstein Director | Apr 26, 2023 | Option exercise | +6,050 | – | – | 8,346 |
| Wayne Remell Walker Director | Apr 26, 2023 | Option exercise | +6,050 | – | – | 8,314 |
| Joshua Silverman Director | Apr 26, 2023 | Option exercise | +6,722 | – | – | 11,237 |
| Greg Bradley Director | Apr 26, 2023 | Option exercise | +6,050 | – | – | 8,314 |
| Wayne Remell Walker Director | Jan 20, 2023 | Option exercise | +2,264 | – | – | 2,264 |
| Bruce Bernstein Director | Jan 20, 2023 | Option exercise | +2,264 | – | – | 2,296 |
| Joshua Silverman Director | Jan 20, 2023 | Option exercise | +2,515 | – | – | 4,515 |
| Greg Bradley Director | Jan 20, 2023 | Option exercise | +2,264 | – | – | 2,264 |
| Juggernaut Partners III GP, L.P. 10% owner | Dec 22, 2021 | Buy | +145,773 | $3.43 | $500.00K | 5,703,544 |
| Juggernaut Partners III GP, Ltd. 10% owner | Nov 29, 2021 | Buy | +500,000 | $3.00 | $1.50M | 5,557,771 |
| John D. Shulman Director, 10% owner | Oct 18, 2021 | Buy | +1,661,807 | $1.72 | $2.86M | 5,057,771 |
| Juggernaut Partners III GP, L.P. 10% owner | Dec 1, 2020 | Award | +3,395,964 | – | – | 3,395,964 |
| Keith Lavan Chief Financial Officer | Dec 1, 2020 | Award | +975 | – | – | 975 |
| Andrew Gesek President, Timm Medical | Dec 1, 2020 | Award | +97 | – | – | 97 |
| John D. Shulman Director, 10% owner | Dec 1, 2020 | Award | +3,382,416 | – | – | 3,382,416 |
| Joshua Silverman Director | Dec 1, 2020 | Award | +20,000 | – | – | 20,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.